Genomic DNA amplification and the detection of t(2;5)(p23;q35) in lymphoid neoplasms.

Anaplastic large cell lymphoma (ALCL) is an intermediate grade Non-Hodgkin's lymphoma (NHL) characterized by the frequent presence of the t(2;5)(p23;q35). This translocation fuses the nucleophosmin (NPM) gene on chromosome 5q35 to a protein kinase gene (Anaplastic Lymphoma Kinase, ALK) on chromosome 2p23. In order to determine the frequency of t(2;5) we used a DNA polymerase chain reaction (PCR) amplification using genomic DNA, 5'-primers derived from the NPM gene, and 3'-primers derived from the ALK gene. The presence of amplifiable DNA in the samples was established with PCR and oligonucleotide primers designed to amplify a 3,016 bp fragment from the beta-globin locus. The t(2;5) PCR assay was established using DNA isolated from three t(2;5)-positive ALCL cell lines. Its ability to amplify genomic DNA prepared for routine molecular diagnostic use was validated using archival DNA from four ALCL tumors known to be t(2;5)-positive. Its sensitivity was established by serially diluting t(2;5)-positive DNA in normal DNA: amplicons were generated in 100% of reactions diluted 10(4)-fold (6-8 cells per tube) and in 30% of those diluted 10(5)-fold (0.6-0.8 cells per tube.) We subsequently analyzed archival genomic DNA extracted from 38 ALCL, 77 NHLs, 37 Hodgkin's lymphomas, and 9 lymphomatoid papuloses. The t(2;5) was detected in 6 ALCLs (16%, 95% confidence intervals 6%-31%), but not in any other lymphoma, or in lymphomatoid papulosis. By using the published sequence of the fourth NPM intron that is involved in t(2;5) and by sequencing the individual tumor amplicons and also the normal ALK intron that is involved in t(2;5), we established that all breakpoints involve the same introns in the ALK and NPM loci. Detailed analysis demonstrated that each translocation generates a unique breakpoint sequence, and suggested that sequence homology between the ALK and NPM intron sequences may be involved in the translocation. We conclude that genomic DNA-PCR is useful for the detection of t(2;5) that in our patient population is restricted to ALCL and is not detectable in other NHL, Hodgkin's disease, or lymphomatoid papulosis. More work is needed to determine the prognostic significance of t(2;5), and to establish the utility of the genomic DNA PCR in monitoring minimal residual disease.

[1]  Z. Xie,et al.  Isolation and characterization of the human nucleophosmin/B23 (NPM) gene: identification of the YY1 binding site at the 5' enhancer region. , 1997, Nucleic acids research.

[2]  K. Pulford,et al.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. , 1997, Blood.

[3]  M. Waasdorp,et al.  Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. , 1996, Blood.

[4]  P. Dubus,et al.  Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. , 1996, The American journal of pathology.

[5]  D. Seiffert,et al.  Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. , 1996, Blood.

[6]  W. Chan,et al.  Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. , 1996, Blood.

[7]  M. Kadin,et al.  The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. , 1996, Blood.

[8]  W. Chan,et al.  Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. , 1995, Blood.

[9]  E. Jaffe,et al.  Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. , 1995, Blood.

[10]  S. Mori,et al.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. , 1995, Leukemia.

[11]  H. Stein,et al.  ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease. , 1995, Blood.

[12]  J. Downing,et al.  Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. , 1995, Blood.

[13]  S. Pileri,et al.  Anaplastic large cell lymphoma: update of findings. , 1995, Leukemia & lymphoma.

[14]  C. Glackin,et al.  Absence of the t(2;5) in Hodgkin's disease. , 1995, Blood.

[15]  D. Mason,et al.  Detection of NPM‐ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma , 1995, British journal of haematology.

[16]  D. Weisenburger,et al.  Lymphomatoid Papulosis: A T-Cell Dyscrasia with a Propensity To Transform into Malignant Lymphoma , 1995, Annals of Internal Medicine.

[17]  A. Feller,et al.  Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis? , 1995, The Lancet.

[18]  H. Satoh,et al.  Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. , 1994, Blood.

[19]  C. Pui,et al.  Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). , 1994, Blood.

[20]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[21]  E. Cesarman,et al.  Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation. , 1994, Blood.

[22]  H. Satoh,et al.  Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. , 1994, Oncogene.

[23]  S. Pileri,et al.  Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. , 1994, Cancer research.

[24]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[25]  S. Pileri,et al.  Anaplastic large cell lymphoma (CD30+/Ki‐1+): results of a prospective clinico‐pathological study of 69 cases , 1994, British journal of haematology.

[26]  V. Zagonel,et al.  Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. , 1994, Blood.

[27]  J. Whitlock,et al.  A Small‐Cell‐Predominant Variant of Primary Ki‐1 (CD30)+ T‐Cell Lymphoma , 1993, The American journal of surgical pathology.

[28]  C. Morton,et al.  Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. , 1992, The New England journal of medicine.

[29]  H. Stein,et al.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.

[30]  J. Hainsworth,et al.  Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Stein,et al.  The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  S. Pileri,et al.  Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study. , 1990, The American journal of pathology.

[33]  H. Stein,et al.  Comparison of Anaplastic Large Cell Ki‐1 Lymphomas and Microvillous Lymphomas in their Immunologic and Ultrastructural Features , 1990, The American journal of surgical pathology.

[34]  C. Fletcher,et al.  Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. , 1990, The American journal of surgical pathology.

[35]  M. Ladanyi,et al.  Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma. , 1990, Leukemia.

[36]  A. Chott,et al.  Ki‐1‐Positive Large Cell Lymphoma: A Clinicopathologic Study of 41 Cases , 1990, The American journal of surgical pathology.

[37]  S. Pileri,et al.  Lymphohistiocytic T‐cell lymphoma (anaplastic large cell lymphoma CD30+/Ki‐1 + with a high content of reactive histiocytes) , 1990, Histopathology.

[38]  R. Larson,et al.  Morphology in Ki‐1 (CD30)‐Positive Non Hodgkin's Lymphoma Is Correlated with Clinical Features and the Presence of a Unique Chromosomal Abnormality, t(2;5)(p23;q35) , 1990, The American journal of surgical pathology.

[39]  S. Wong,et al.  Anaplastic large cell Ki‐l lymphoma , 1990 .

[40]  R. Warnke,et al.  CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35 , 1990, British journal of haematology.

[41]  R. Larson,et al.  The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. , 1989, Leukemia.

[42]  H. Stein,et al.  Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics. , 1989, The American journal of pathology.

[43]  R. Warnke,et al.  Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis. , 1989, Blood.

[44]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.

[45]  Qing-Rong Liu,et al.  Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. , 1989, Biochemistry.

[46]  P. Sherrington,et al.  A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene , 1988 .

[47]  K. Lennert,et al.  Updated Kiel classification for lymphomas , 1989, The Journal of pathology.

[48]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[49]  V. Diehl,et al.  Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells , 1982, Nature.

[50]  M. Waasdorp,et al.  Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  A. Bernheim,et al.  High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. , 1996, Blood.